BB Biotech AG Shareholders Approve Dividend and Re-Elect Board

BB Biotech AG's shareholders have given their approval to all proposals at the Annual General Meeting held on March 19, 2025. Among the proposals passed, a dividend of CHF 1.80 per share was confirmed. This payment will be processed on March 25, with the record date set for March 24 and the ex-dividend date on March 21.

In addition to the dividend approval, shareholders re-elected the existing board members for another term. The board, comprising Dr. Thomas von Planta, Dr. Clive Meanwell, Laura Hamill, Dr. Pearl Huang, Prof. Dr. Mads Krogsgaard Thomsen, and Camilla Soenderby, will continue to guide the company’s strategic direction.

BB Biotech AG invests in innovative drug developers, primarily in the US and Western Europe, and is considered one of the largest investors in this sector globally.